Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofoctol SCHEMBL29397347 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL71922 | 0.85 | CYP3A4 (0.73) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL16656147 | 0.80 | CYP3A4 (0.66) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL27365508 | 0.76 | CYP3A4 (0.61) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL9082692 | 0.76 | CYP3A4 (0.60) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL27365471 | 0.75 | CYP3A4 (0.60) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL9814995 | 0.75 | KLF10 (0.68) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL5964677 | 0.75 | CYP3A4 (0.65) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL8163543 | 0.74 | MAPT (0.59) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL10802800 | 0.74 | SMN1; SMN2 (0.58) | CYP3A4MEN1KMT2AUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | claimed |
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| WO-2024223624-A1 | NEW CLOFOCTOL FORMULATION | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-10-31 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| EP-4164749-B1 | COMPOUND AND METHOD FOR THE TREATMENT OF CORONAVIRUSES | APTEEUS (FR) | 2024-08-07 | — | — | EP | claimed |
| US-20240238217-A1 | USE OF CLOFOCTOL FOR THE TREATMENT OF INFLAMMATION | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE (FR) | 2024-07-18 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| WO-2024086533-A2 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING CDC7 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-04-25 | — | — | WO | claimed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| US-5811078-A | IN A SOLVENT MIXTURE WITH ETHYL OR ISOPROPYL ALCOHOL AND WATER | ADOLOR CORPORATION (US) | 1998-09-22 | — | — | US | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | HPGDS, AIPL1, PON1 | CYP3A4 3561/4885MEN1 3237/4885KMT2A 4183/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | CYP3A4 171/4885MEN1 2154/4885KMT2A 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.